OpGen Q1 Revenues More Than Double | GenomeWeb

NEW YORK (GenomeWeb) – OpGen after the close of the market Wednesday reported a 128 percent increase in its first quarter revenues.

For the three months ended March 31, the Gaithersburg, Maryland-based infectious disease testing and bioinformatics firm reported revenues of $1.1 million, up from $472,200 in the first quarter of 2015. The rise is attributable to sales of AdvanDx diagnostic products and CLIA laboratory services provided using the Acuitas multi-drug resistant organisms testing suite, OpGen Chairman and CEO Evan Jones said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.